Literature DB >> 26147294

A Novel Insertion Variant of CRYGD Is Associated with Congenital Nuclear Cataract in a Chinese Family.

Xiaotong Zhuang1, Lianqing Wang2, Zixun Song3, Wei Xiao3.   

Abstract

OBJECTIVE: To investigate a novel insertion variant of CRYGD identified in a Chinese family with nuclear congenital cataract.
METHODS: A Chinese family with congenital nuclear cataract was recruited for the mutational screening of candidate genes by direct sequencing. Recombinant N-terminal Myc tagged wildtype or mutant CRYGD was expressed in HEK293T cells. The expression pattern, protein solubility and subcellular distribution were analyzed by western blotting and immunofluorescence. PRINCIPAL
FINDINGS: A novel insertion variant, c.451_452insGACT, in CRYGD was identified in the patients. It causes a frameshift and a premature termination of the polypeptide to become Y151*. A significantly reduced solubility was observed for this mutant. Unlike wildtype CRYGD, which existed mainly in the cytoplasm, Y151* was mis-located in the nucleus.
CONCLUSIONS: We have identified a novel mutation, c.451_452insGACT, in CRYGD, which is associated with nuclear cataract. This is the first insertion mutation of CRYGD found to cause autosomal dominant congenital cataract. The mutant protein, with loss of solubility and localization to the nucleus, is hypothesized to be the major cause of cataract in these patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26147294      PMCID: PMC4493073          DOI: 10.1371/journal.pone.0131471

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Congenital cataracts are a major cause of visual impairment and blindness in childhood [1]. The estimated prevalence is 1–6 per10,000 live births, approximately one-third of which are believed to be inherited [2, 3]. Inherited cataracts are clinically highly heterogeneous, commonly exhibiting considerable inter- and intrafamilial phenotypic variation [4]. In non-consanguineous populations, inherited cataracts most frequently show an autosomal dominant pattern of inheritance, while autosomal recessive and X-linked patterns have also been reported [2, 5]. To date, more than 20 independent genes on different chromosomes have been shown to be associated with isolated congenital cataracts [6]. Among the congenital cataract families with causative mutations discovered so far, about half have mutations in crystallins, with the remainder divided among the genes for gap junction proteins, transcription factors, membrane transporter proteins, and cytoskeletal proteins [7]. Nuclear cataract, which was first described by Brown in 1924, is one of the most familiar types of severe congenital cataract [8, 9]. The visual acuity is remarkably reduced in patients with this kind of cataract because the opacity is located at the center of the lens [10]. Currently, autosomal dominant congenital nuclear cataracts have been linked to 11 specific causative genes [7], and most of the mutations are in the crystallin family of genes [9, 11–15]. In the present study, a four-generation Chinese family with congenital nuclear cataract was recruited. We identified a novel four-base insertion, namely c.451_452insGACT, in exon 3 of CRYGD after sequencing the candidate crystallin genes. This change led to a truncated protein Tyr151*. The mutant CRYGD exhibited reduced solubility, and localized incorrectly to the cell nucleus. To our knowledge, this is the first insertion mutation of CRYGD found to be disease-causing in congenital cataract.

Methods

Study samples

We collected blood samples from seven members (three affected and four unaffected) of a four-generation Han Chinese family with autosomal dominant nuclear cataract (Fig 1A) after obtaining informed consent and approval of the China Medical University Review Board. One hundred and three unrelated individuals were also recruited as study controls. Peripheral blood samples were collected for DNA analysis.
Fig 1

The family with congenital nuclear cataract.

(A) Pedigree of the Chinese family with autosomal dominant nuclear cataract. Squares and circles indicate males and females, respectively. Black symbols represent individuals with a cataract phenotype and open symbols represent unaffected individuals. The proband is marked by an arrow. The numbers of the participants in this study are indicated by red color. (B) Lens picture from the proband showed the opacities located in the lens nucleus and that the sutures were also involved (right eye).

The family with congenital nuclear cataract.

(A) Pedigree of the Chinese family with autosomal dominant nuclear cataract. Squares and circles indicate males and females, respectively. Black symbols represent individuals with a cataract phenotype and open symbols represent unaffected individuals. The proband is marked by an arrow. The numbers of the participants in this study are indicated by red color. (B) Lens picture from the proband showed the opacities located in the lens nucleus and that the sutures were also involved (right eye).

Mutation screening and sequence analysis

Genomic DNA was extracted from 500 μL of peripheral blood using a TIANamp Blood DNA Midi Kit (Tiangen, Beijing, China). After genomic polymerase chain reaction (PCR) performed, we sequenced the coding exons and their flanking intronic sequences of six crystallin family genes CRYAA, CRYBA1, CRYBB1, CRYBB2, CRYGC and CRYGD, for pathogenic mutations in the proband. The primers and reaction conditions used in PCR have been described in earlier reports [16-21]. To more clearly show the mutation c.451_452insGACT in CRYGD, the obtained fragment was cloned into pMD-18T vector (TaKaRa, Dalian, China) and sequenced. To confirm the mutation, we performed genomic polymerase chain reaction (PCR) using primers CRYGD forward (5’-TACGAGCTGTCCAACTACCGAG-3’) and reverse (5’-GAGAAATCTATGACTCTCCTCAG-3’) in the family and 103 unrelated individuals. The PCR fragments were separated by 8% polyacrylamide gel electrophoresis. The analysis of amino acid conservation around the mutation site was carried out by CLC DNA Workbench.

Minigene assay

Genomic DNA fragments containing partial exon 2, intron 2 and partial exon 3 (the sequence before AAUAAA signal) were generated by PCR using primers CRYGD-2Fm (5’-ATCA) and CRYGD-3Rm (5’-TGA). The PCR fragments were cloned into the vector pcDNA3.1 (+) (Invitrogen, California, USA) at the BamH I and EcoR I sites. The constructs with the wildtype or mutant genomic inserts were verified by direct sequencing. The constructs were individually transfected into HEK293T or SRA 01/04 cells. For RT-PCR, total RNA was isolated using the Trizol reagent (Invitrogen) from the transfected cells and reverse transcription was performed using the PrimeScript 1st Strand cDNA Synthesis Kit (TaKaRa). PCR was then carried out with primers CRYGD-2FS (5’-GACTATGCCGACCACCAGCAG-3’) and pcDNA-R (5’-AACTAGAAGGCACAGTCGAGG-3’). The PCR products were sequenced using the primer CRYGD-2FS.

Bioinformatics analysis

The effect of the mutation c.451_452insGACT on splicing was predicted by Augustus (http://augustus.gobics.de/). The secondary structures of CRYGD were predicted by the GOR4 Secondary Structure Prediction Method. The protein physical and chemical parameters of the CRYGD protein were analyzed by ProtParam (http://web.expasy.org/protparam/). We also used the BEST/COREX server (http://best.bio.jhu.edu/BEST/index.php) to predict the stability of the wildtype and mutant proteins.

Plasmid constructs

The human CRYGD (GeneBank NM_006891.3) cDNA, encoding 174 amino acid residues, was obtained by PCR amplification from a Human Multiple Tissue cDNA Panel (Ovary tissue, BD, New Jersey, USA) and cloned into pCMV-Myc vector (Clontech, New Jersey, USA) at the site of EcoR I and Bgl II action. The primers used in the CRYGD construct were: sense 5’-TCCTGAATTCCCATGGGGAAGATCACCCTC-3Y and antisense 5Y-GGATAGATCTTCAGGAGAAATCTATGACTC-3’. The Y151* mutant was constructed by site-directed mutagenesis with the following primer: sense 5’-CTGCTGATGCCAGGG; antisense 5’-GTAGCGCCTATAGTC (the underline indicates the position of the base insertion). All the constructs were confirmed by direct sequencing.

Cell culture and transfection

Human embryonic kidney (HEK) 293T cells and human lens epithelium lines SRA 01/04 (Cell Resource Center, IBMS, CAMS&PUMC) were routinely grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FBS at 37°C with 5% CO2. For transfection with plasmid DNA, the cells were cultured on six-well plates at 50% confluence, grown overnight, then transfected with the constructs using Lipofectamine 2000 (Invitrogen).

Protein over-expression analysis

After 36 h of transfection, the cultured HEK293T cells were harvested and lysed in RIPA buffer (1% NP-40, 0.5% deoxycholate, 0.1% SDS) (Beyotime, Shanghai, China) containing protease inhibitor cocktail (Roche, Basel, Switzerland) for 1h at 4°C. Centrifuge the samples at 12,000×g for 10 min at 4°C. The supernatant was collected and denatured in SDS loading buffer (TaKaRa). The precipitants containing insoluble proteins were washed three times with ice-cold PBS, sonicated, and denatured in SDS loading buffer containing 6 mol/L urea. After boiling, the protein samples were separated by 12% SDS-polyarcylamide gel electrophoresis (PAGE) and then transferred to PVDF membranes (Millipore, Massachusetts, USA). The membranes were blocked with TBS buffer (pH 7.4) containing 0.05% Tween-20 and 5% nonfat milk. The blotted proteins were probed with anti-Myc antibody (9E10) (Santa Cruz Biotechnology, Santa Cruz, USA) or anti-β-actin antibody (ZSGB-Bio, Beijing, China), followed by incubation with Goat anti-Mouse IgG (H+L) (peroxidase conjugated) (Pierce, Illinois, USA). The blots were developed subsequently with an enhanced chemiluminescence (ECL) system (Pierce).

Immunofluorescence

HEK293T cells grown on glass coverslips were fixed with 4% paraformaldehyde (Sigma Aldrich, Shanghai, China), permeabilized with 0.05% Triton-X 100, and blocked with 5% bovine serum albumin (BSA). Anti-Myc antibody (9E10) incubations were carried out in 5% BSA at a dilution of 1:200. After incubation, the cells were washed with PBS three times. The secondary antibody conjugated DyLight 488 (EarthOx, California, USA) (1:800) was added; this had been tested and no cross-reactivity found. The nucleus was stained with 500 ng/ml DAPI (Sigma Aldrich). Following three final washes with PBS, coverslips were mounted in antifade reagent (Beyotime). The samples were examined by fluorescence microscopy equipped with a DP controller system (DP70, Olympus, Japan).

Results

Clinical features

We ascertained a four-generation Chinese family with autosomal dominant nuclear congenital cataracts (Fig 1A). All affected individuals showed nuclear cataract, which presented several months after birth. The visual acuity was impaired gradually as the lens opacity increased, and was seriously reduced at 12–13 years old. We failed to get the visual acuity of proband because she is in early childhood (S1 Table). The affected individuals showed an opacity in the central nucleus region of both lenses. The Y-sutures were also involved with prominent opacity (Fig 1B). No systemic disease or other ocular disease was found.

Mutation confirmation in CRYGD

Mutation screenings were performed for all six candidate crystallin genes, and a heterozygous variant, c.451_452insGACT, was identified in exon 3 of CRYGD (Fig 2A). The variant led to the substitution of a newly formed stop codon for a phylogenetically conserved tyrosine residue (p.Tyr151*) (Fig 2B), and was only identified in the affected individuals. With the exception of several nonpathogenic SNPs, no other variants were detected. On polyacrylamide gel electrophoresis, the variant was confirmed in all affected individuals but was not detected in unaffected family members or 103 unrelated Chinese controls (Fig 2C).
Fig 2

Confirmation of the c.451_452insGACT (p.Tyr151*) insertion mutation of CRYGD.

(A) Sequence chromatogram showing the heterozygous c.451_452insGACT insertion mutation of CRYGD in the proband. The mutation was numbered according to GenBank NM_006891.3. (B) Polyacrylamide gel electrophoresis showing different sizes of the PCR fragments in the pedigree. The 134 bp and 130 bp fragments were amplified from affected and unaffected chromosome, respectively. (C) Protein alignment of mammalian samples showing that the regions around the mutation are highly conserved. Numbers on left and right indicate the position of this fragment. The position of the mutant is marked by a black triangle.

Confirmation of the c.451_452insGACT (p.Tyr151*) insertion mutation of CRYGD.

(A) Sequence chromatogram showing the heterozygous c.451_452insGACT insertion mutation of CRYGD in the proband. The mutation was numbered according to GenBank NM_006891.3. (B) Polyacrylamide gel electrophoresis showing different sizes of the PCR fragments in the pedigree. The 134 bp and 130 bp fragments were amplified from affected and unaffected chromosome, respectively. (C) Protein alignment of mammalian samples showing that the regions around the mutation are highly conserved. Numbers on left and right indicate the position of this fragment. The position of the mutant is marked by a black triangle.

The mutation has no effect on splicing

To investigate whether c.451_452insGACT has effect on splicing, it was predicted by Augustus. It showed the splicing was not affected by the mutation (data not shown). To confirm the result, minigene assay was performed. Using primers from exon 2 and pcDNA 3.1, PCR was carried out to analyze the transcription fragments. There were no obvious difference in the length between wildtype and mutant (Figure B in S1 File). Consistent with the results of bioinformatics analysis, splicing was not affected by the mutation c.451_452insGACT, which was confirmed by direct sequencing (Figure C in S1 File).

Bioinformatics analysis of Y151* on protein level

The mutant protein was truncated by 24 amino acids at the C-terminus when compared with the wildtype, and the fourth Greek key motif (amino acid 129–171) was partially absent. Both the extended strand and the random coil were reduced, resulting in destruction of the secondary structure (Fig 3A). The truncated CRYGD had an acidic isoelectric point (PI), which may be involved in protein aggregation. The mutation rendered CRYGD more unstable and decreased its solubility (Table 1). Moreover, the stability constant (Kf) at the per residue level showed that the mutant CRYGD favored the unfolded states at the C-terminus (Fig 3B).
Fig 3

Bioinformatics analysis of the mutant CRYGD Y151*.

(A) The predicted secondary structure showing the reduced extended strand and random coil in the mutant. (B) The C-terminal domain of the truncated CRYGD favors the unfolded state. The residue-specific stability constant (Kf) for each residue of the protein was predicted by the BEST/COREX server.

Table 1

Comparison of CRYGD wildtype and mutant.

Protein characteristicsWTY151*
Number of amino acids 174150
Theoretical PI 7.006.05
Instablity index 54.8956.82
Aliphatic index 63.8563.67
Grand average of hydropathicity -0.804-0.799

The physical and chemical parameters of the protein were analyzed by ProtParam.

Bioinformatics analysis of the mutant CRYGD Y151*.

(A) The predicted secondary structure showing the reduced extended strand and random coil in the mutant. (B) The C-terminal domain of the truncated CRYGD favors the unfolded state. The residue-specific stability constant (Kf) for each residue of the protein was predicted by the BEST/COREX server. The physical and chemical parameters of the protein were analyzed by ProtParam.

The mutant CRYGD has decreased solubility

Myc-tagged wildtype and Y151* CRYGD constructs were transiently expressed in HEK293T cells and were detected using anti-Myc antibody (9E10). Western blotting showed that the molecular weight of recombinant mutant CRYGD had decreased as a result of the loss of 24 amino acids (Fig 4A, upper). Moreover, the mutant CRYGD had a greatly reduced level of protein level in the supernatant when compared with wildtype (Fig 4A, upper; Fig 4B). The mutant protein aggregated mainly in the precipitant where the wildtype was not detected (Fig 4A, lower). The results indicated that the mutant protein possessed decreased solubility.
Fig 4

Western blot analysis of CRYGD over-expression in HEK293T cells.

(A) The truncated CRYGD showed decreased solubility. In the supernatant, the mutant protein was truncated and was present in much lower amounts than the wildtype. In the precipitant, there was more mutant protein and the wildtype was not detected. (B) Quantification by band densitometry indicated the prominent reduction of mutant CRYGD in the supernatant (p<0.05).

Western blot analysis of CRYGD over-expression in HEK293T cells.

(A) The truncated CRYGD showed decreased solubility. In the supernatant, the mutant protein was truncated and was present in much lower amounts than the wildtype. In the precipitant, there was more mutant protein and the wildtype was not detected. (B) Quantification by band densitometry indicated the prominent reduction of mutant CRYGD in the supernatant (p<0.05).

Mis-localization of mutant CRYGD to the cell nucleus

To confirm the pathogenicity of the mutation Y151*, immunofluorescence assay was performed to detect the subcellular localization of mutant CRYGD. Myc-tagged wildtype CRYGD was localized in both cytoplasmic and membrane regions, whereas Y151* was redistributed in the nucleus as a spot-shaped structure (Fig 5). Minimal staining in the cytoplasm was also observed. The aggregation of the mutant protein in the nucleus showed that it failed to form crystallin and perform its intrinsic function.
Fig 5

Localization of Myc-tagged wildtype or Y151* CRYGD in HEK293T cells.

Immunofluorescence of Myc (green fluorescence) showed the distribution of wildtype CRYGD in both cytomembrane and cytoplasm. However, the mutant CRYGD was mainly localized in the nucleus, in the form of granular deposits. Scale bar: 10 μm.

Localization of Myc-tagged wildtype or Y151* CRYGD in HEK293T cells.

Immunofluorescence of Myc (green fluorescence) showed the distribution of wildtype CRYGD in both cytomembrane and cytoplasm. However, the mutant CRYGD was mainly localized in the nucleus, in the form of granular deposits. Scale bar: 10 μm.

Discussion

In this study, we identified a novel deletion mutation (c.451_452insGACT) in CRYGD, which caused a truncated polypeptide (p.Tyr151*). Our expression studies demonstrated that the mutant was highly insoluble and had an abnormal location. The mutant CRYGD may affect lens fiber differentiation thus interfering with lens transparency [22]. Lens transparency is maintained mainly by structural crystallins. Crystallins consist of a core set of three protein families, the α-, β- and γ-crystallins, which are defined by the sizes of the oligomers that they form [23]. Alteration of both the function and the molecular properties of crystallins may cause the breakdown of lens microstructure, which results in changes in the refractive index and increased light scattering [22]. γD-crystallin, encoded by CRYGD, is one of the important crystallins. An impairment in γD-crystallin expression may be responsible for cataract [3, 22]. γD-crystallin is composed of two individual domains that each consist of two Greek key motifs (GKM) [3]. Each GKM is composed of four antiparallel β-strands. Up to 2015, a total of 19 mutations in CRYGD were reported responsible for cataracts, most of which are missense mutations. However, little functional importance of the mutants was illustrated in the previous reports (S2 Table.). All the mutations distribute in the four GKMs. Intriguingly, the truncated mutations are mainly in the GKM4 of the C-terminus (5/7) (S1 Fig). However, the nonsense mutation c.51T>G (Y17*) and c.168C>G (Y56*) Also, the Y151* mutation is located in the same domain. The insertion c.451_452insGACT in exon 3 of CRYGD is predicted to cause a premature stop codon, which leads to the deletion of the C-terminal residues 151–174 (Fig 3A). As shown in the diagram (Fig 3B), the truncated protein destabilizes the C-terminal domain. Moreover, the aggregation state of the mutant γD-crystallin was also affected (Fig 5). Several usually buried residues of the mutant γD-crystallin may be exposed on the surface, which means that the protein displays lower solubility and structural stability [24]. The loss of the C-terminal tail in γD-crystallin leads to substantial intermolecular aggregation, which generates light-scattering particles [25]. It is unclear why the aggregated mutant γD-crystallin was located in the nucleus. There are no amino acid residues related to nuclear localization in the lost C-terminal tail. Asp156, Arg163 and Arg168, the charged residues of wildtype γD-crystallin, are involed in charge interactions [26]. They may play an important role in the processing and subcellular localization of the protein [27]. It will be intriguing to explore how the incorrect localization may have resulted from alteration of the physicochemical properties of the protein. In summary, we have identified c.451_452insGACT as a novel causative mutation in CRYGD responsible for autosomal dominant congenital nuclear cataract. Our results provide a novel insight into the molecular mechanisms involving CRYGD that underlie the pathogenesis of human congenital cataract.

The distribution of mutations in CRYGD responsible for cataracts.

(TIF) Click here for additional data file.

The effect of the mutation c.451_452insGACT on splicing.

The schematic diagram of DNA fragments used in the constructs (Figure A). Agarose gel electrophoresis showing no difference in the PCR fragments between wildtype and mutant (Figure B). Sequence chromatogram showing the c.451_452insGACT mutation has no effect on splicing (Figure C). (TIF) Click here for additional data file.

Clinical information of the family members.

(PDF) Click here for additional data file.

γD-crystallin mutations, related phenotypes and functional changes.

(PDF) Click here for additional data file.
  26 in total

1.  Two affected siblings with nuclear cataract associated with a novel missense mutation in the CRYGD gene.

Authors:  Olga Maud Messina-Baas; Luz Maria Gonzalez-Huerta; Sergio Alberto Cuevas-Covarrubias
Journal:  Mol Vis       Date:  2006-08-24       Impact factor: 2.367

2.  CRYBB1 mutation associated with congenital cataract and microcornea.

Authors:  Colin E Willoughby; Ayad Shafiq; Walter Ferrini; Louie Loh Yen Chan; Gail Billingsley; Megan Priston; Calvin Mok; Arvind Chandna; Stephen Kaye; Elise Héon
Journal:  Mol Vis       Date:  2005-08-08       Impact factor: 2.367

Review 3.  Age-related nuclear cataract-oxidation is the key.

Authors:  Roger J W Truscott
Journal:  Exp Eye Res       Date:  2005-05       Impact factor: 3.467

4.  Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins.

Authors:  L Cocquerel; C Wychowski; F Minner; F Penin; J Dubuisson
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  The gamma-crystallins and human cataracts: a puzzle made clearer.

Authors:  E Héon; M Priston; D F Schorderet; G D Billingsley; P O Girard; N Lubsen; F L Munier
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

6.  Cell death triggered by a novel mutation in the alphaA-crystallin gene underlies autosomal dominant cataract linked to chromosome 21q.

Authors:  Donna S Mackay; Usha P Andley; Alan Shiels
Journal:  Eur J Hum Genet       Date:  2003-10       Impact factor: 4.246

7.  A deletion mutation in the betaA1/A3 crystallin gene ( CRYBA1/A3) is associated with autosomal dominant congenital nuclear cataract in a Chinese family.

Authors:  Yanhua Qi; Hongyan Jia; Shangzhi Huang; Hui Lin; Jingzhi Gu; Hong Su; Tieying Zhang; Ya Gao; Lijun Qu; Dandan Li; Ying Li
Journal:  Hum Genet       Date:  2003-11-04       Impact factor: 4.132

8.  Autosomal dominant congenital cataract. Interocular phenotypic variability.

Authors:  M H Scott; J F Hejtmancik; L A Wozencraft; L M Reuter; M M Parks; M I Kaiser-Kupfer
Journal:  Ophthalmology       Date:  1994-05       Impact factor: 12.079

9.  High-resolution X-ray crystal structures of human gammaD crystallin (1.25 A) and the R58H mutant (1.15 A) associated with aculeiform cataract.

Authors:  Ajit Basak; Orval Bateman; Christine Slingsby; Ajay Pande; Neer Asherie; Olutayo Ogun; George B Benedek; Jayanti Pande
Journal:  J Mol Biol       Date:  2003-05-16       Impact factor: 5.469

10.  A nonsense mutation of γD-crystallin associated with congenital nuclear and posterior polar cataract in a Chinese family.

Authors:  Yi Zhai; Jinyu Li; Yanan Zhu; Yan Xia; Wei Wang; Yinhui Yu; Ke Yao
Journal:  Int J Med Sci       Date:  2014-01-05       Impact factor: 3.738

View more
  5 in total

Review 1.  Inherited Congenital Cataract: A Guide to Suspect the Genetic Etiology in the Cataract Genesis.

Authors:  Olga Messina-Baas; Sergio A Cuevas-Covarrubias
Journal:  Mol Syndromol       Date:  2017-02-07

2.  Molecular Etiology of Isolated Congenital Cataract Using Next-Generation Sequencing: Single Center Exome Sequencing Data from Turkey.

Authors:  Hande Taylan Sekeroglu; Beren Karaosmanoglu; Ekim Z Taskiran; Pelin O Simsek Kiper; Mehmet Alikasifoglu; Koray Boduroglu; Turgay Coskun; Gulen Eda Utine
Journal:  Mol Syndromol       Date:  2020-09-09

Review 3.  Genes and genetics in eye diseases: a genomic medicine approach for investigating hereditary and inflammatory ocular disorders.

Authors:  Mahavir Singh; Suresh C Tyagi
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

4.  A novel truncation mutation in CRYBB1 associated with autosomal dominant congenital cataract with nystagmus.

Authors:  Yan Rao; Sufang Dong; Zuhua Li; Guohua Yang; Chunyan Peng; Ming Yan; Fang Zheng
Journal:  Mol Vis       Date:  2017-09-01       Impact factor: 2.367

5.  Two Pathogenic Gene Mutations Identified Associating with Congenital Cataract and Iris Coloboma Respectively in a Chinese Family.

Authors:  Bin Li; Bin Lu; Xuewen Guo; Shenghui Hu; Guihu Zhao; Weihong Huang; Jianzhong Hu; Kun Song
Journal:  J Ophthalmol       Date:  2020-02-19       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.